Depikus, a company at the forefront of interectomy, has been recognized for their groundbreaking technology with the Society for Laboratory Automation and Screening’s (SLAS) prestigious Ignite Award. The award was presented at the SLAS annual international conference and exhibition in Boston, MA, where Depikus also unveiled their MAGNA One™ instrument.
The Ignite Award is given to companies that are revolutionizing the life sciences through innovative technologies. Entries were evaluated by a panel of experts based on various criteria, including excellence in innovation, marketing presence, impact, funding and balanced leadership. Depikus was one of only 16 companies selected to participate in the SLAS2024 Innovation AveNEV program, a dedicated area for start-ups and emerging companies within the conference. Out of those 16 companies, eight were chosen as finalists for the Ignite Award.
MAGNA One is based on magnetic force spectroscopy, allowing for high-throughput analysis of dynamic biomolecular interactions. This technology is the first to offer real-time measurements of thousands of individual molecules simultaneously, making it particularly useful for investigating challenging targets such as RNA and protein-protein interactions. It provides valuable insight into disease mechanisms and accelerates the development of new therapeutics.
Depikus CEO Gordon Hamilton expressed his excitement about winning the Ignite award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are desperately needed. Chief Commercial Officer Steve Klose added that the timing of the award coincides with the launch of their technology access program and the commercial introduction of MAGNA One, marking a significant moment for Depikus.
For more information about Depikus and their MAGNA One™ instrument, visit depikus.com or contact Steve Klose at firstname.lastname@example.org